ASCO 2021: Addition of Abiraterone to Standard of Care Improved Radiographic Progression-Free Survival in Metastatic Prostate Cancer
Author suggests abiraterone-prednisone should be part of standard of care in de novo metastatic prostate cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.